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There is considerable interest in developing highly selective dopamine (DA) D3 receptor
ligands for a variety of mental health disorders. DA D3 receptors have been implicated in
Parkinson’s disease, schizophrenia, anxiety, depression, and substance use disorders. The
most concrete evidence suggests a role for the D3 receptor in drug-seeking behaviors.
D3 receptors are a subtype of D2 receptors, and traditionally the functional role of these
two receptors has been difﬁcult to differentiate. Over the past 10–15 years a number of
compounds selective for D3 over D2 receptors have been developed. However, translating
these ﬁndings into clinical research has been difﬁcult as many of these compounds cannot
be used in humans.Therefore, the functional data involving theD3 receptor in drug addiction
mostly comes from pre-clinical studies. Recently, with the advent of [11C]-(+)-PHNO, it has
become possible to image D3 receptors in the human brain with increased selectivity and
sensitivity. This is a signiﬁcant innovation over traditional methods such as [11C]-raclopride
that cannot differentiate between D2 and D3 receptors. The use of [11C]-(+)-PHNO will
allow for further delineation of the role of D3 receptors. Here, we review recent evidence
that the role of the D3 receptor has functional importance and is distinct from the role of the
D2 receptor.We then introduce the utility of analyzing [11C]-(+)-PHNO binding by region of
interest. This novel methodology can be used in pre-clinical and clinical approaches for the
measurement of occupancy of both D3 and D2 receptors. Evidence that [11C]-(+)-PHNO
can provide insights into the function of D3 receptors in addiction is also presented.
Keywords: dopamine, occupancy, PET imaging, D3, D2
INTRODUCTION
Dopamine (DA) is a neurotransmitter that has been implicated
in a variety of psychiatric disorders such as Parkinson’s disease,
schizophrenia, and addiction. There has been a great deal of inter-
est in developing drugs that target DA receptors to treat these
various neuro-psychiatric disorders. Five types of DA receptor
subtypes have been identiﬁed and they are broadly classiﬁed as
D1-type and D2-type based on sequence homology and phar-
macology, and numbered in order of their date of cloning. First
described in the early 1990s (Sokoloff et al., 1990),D3 receptors are
a subtype of the previously characterized D2 receptor. Discovery
of this subtype sparked interest in determining the properties and
functions that distinguish it from D2 receptors. It is known that
D3 receptors are metabotropic 7-membrane-spanning receptors
that share overall ∼50% homology with the D2 receptor (Sibley
and Monsma, 1992). Like D2 receptors, the D3 subtype inhibits
adenylyl cyclase (Robinson and Caron, 1996). D3 receptors have
been localized to neurons containing tyrosine hydroxylase suggest-
ing that these receptors are pre-synaptic, corresponding to their
role as autoreceptors (Diaz et al., 2000). This is consistent with
reports that mutant mice lacking the D3 receptors are hyperac-
tive (Xu et al., 1997), presumably due to increases in DA resulting
from a lack of negative feedback normally mediated through D3
autoreceptors.
Historically, D2 receptors have been a treatment target (mostly
for schizophrenia andParkinson’s disease), but the restricted local-
ization of D3 receptors (Bouthenet et al., 1991; Diaz et al., 2000;
Heidbreder, 2005) has led to interest in modulating D3 activity
for the treatment of addiction (Le Foll et al., 2000, 2005c; Joyce
and Millan, 2005), schizophrenia (Gross and Drescher, 2012), and
Parkinson’s disease (Joyce, 2001; see Sokoloff et al., 2006 for a
review). D3 receptors have been found to be localized to the islands
of Calleja, mammillary bodies, accumbens shell, frontoparietal
cortex, the substantia nigra/ventral tegmental area, and cerebel-
lar lobules 9 and 10 (Diaz et al., 2000). As discussed later in this
review, binding of radioligands to D3 receptors in the substan-
tia nigra/ventral tegmental area is used to quantify the level of
binding to D3 receptors, and Figure 1 provides an illustration of
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FIGURE 1 | Distribution of D3 receptors: immunohistochemical
localization of the DRD3 in rat brain. (A,B) Superimposable distributions
of binding of [125I]trans-7-OH-PIPAT, a DRD3-selective ligand (A), and
DRD3 immunoreactivity (B), with highest levels in the islands of Calleja
(IcjM and IC) and moderate levels in the shell of nucleus accumbens (Sh);
ac, anterior commissura. (C,D) Expression of DRD3 immunoreactivity
alone (in red in C) and in combination with tyrosine hydroxylase
immunoreactivity (in green in D). All tyrosine hydroxylase-positive neurons
in the mesencephalon express the DRD3. Distribution of the binding of
[125I]trans-7-OH-PIPAT in SN/VTA of D3R+/+ mice (E) and of D3R−/− mice
(F). Adapted with permission from Diaz et al. (2000).
D3 receptor immunoreactivity in the rodent brain. Figure 1 illus-
trates a great density of D3 receptors in the nucleus accumbens
and substantia nigra/ventral tegmental (Diaz et al., 2000).
Until recently, direct study of the D3 receptor has proven dif-
ﬁcult due to the lack of compounds selective for D3, as opposed
to D2, receptors. Nonetheless, a number of selective antagonists
have been developed, including SB-277011-A (Reavill et al., 2000),
YQA14 (Song et al., 2012), PG01037 (Grundt et al., 2007), NGB
2904 (Yuan et al., 1998; Robarge et al., 2001), GSK 598809 (Dodds
et al., 2012; Nathan et al., 2012; Mugnaini et al., 2013), ABT-925
(Graff-Guerrero et al., 2010), ST 198 (Weber et al., 2001; Le Foll
et al., 2005d), and S33138 (Millan et al., 2008). Pre-clinical stud-
ies utilizing these ligands have supported the view that DA D3
receptor antagonists may be used for the treatment of psychiatric
disorders, notably addiction. Interestingly, pre-clinical ﬁndings
indicate a clear relationship between in vivo occupancy of these
receptors and behavioral response, particularly drug-seeking (see
below). In human trials exploring treatment options, the mea-
surement of occupancy of D3 receptors may thus be critical. To
our knowledge, only a few human trials using a highly selective D3
antagonist (GSK 598809) have been published (Dodds et al., 2012;
Nathan et al., 2012; Mugnaini et al., 2013), yet these trials have
been prematurely stopped. As listed on ClinicalTrials.gov, studies
examining D3 antagonists have been conducted for schizophrenia,
smoking and eating disorders. Generally, clinical investigations
remain in their infancy as few compounds suitable for use in
humans have been developed with selectivity for D3 over D2
receptors.
A recently published review brieﬂy summarized the [11C]-(+)-
PHNO studies conducted in addiction to-date (Payer et al., 2014).
Here, we will additionally explore the importance of differenti-
ating the behaviors mediated by the D3 receptor from the D2
receptor. While the two receptors have historically been difﬁcult to
distinguish, their functions are distinct and therefore further inves-
tigation of D3 receptors is mandated. We will brieﬂy introduce the
published studies that indicate functional differences between D2
and D3 receptors. The present paper will also provide a more com-
prehensive summary of the positron emission tomography (PET)
technique and PET imaging with [11C]-(+)-PHNO. The focus of
this review will be to present novel methods allowing for the mea-
surement of occupancy of D3 receptors in pre-clinical and clinical
approaches using [11C]-(+)-PHNO and PET.
THE IMPORTANCE OF DIFFERENTIATING D3 FROM D2 RECEPTORS
Despite considerable structural homogeneity, growing evidence
suggests that the role of D3 and D2 receptors may be distinct.
Indeed, regulation of receptor expression in various pathologies
appears to differ between D3 and D2. Further, antagonists at the
D2 receptor seem to be less selective in their effects on behavior
which may account for the side effects observed with D2 agents
but not believed to occur with D3 antagonists. D3 antagonists
also have cognitive enhancing properties that are not observed
with D2 antagonists (Nakajima et al., 2013). These ﬁndings are
summarized below.
Differences between D2 and D3 receptors in pathology
Studies exploring the regulation of D2 and D3 receptors in drug
addiction reveal that these receptors are differentially regulated. D2
receptors appear to be downregulated in the brains of individuals
with addictions (Volkow et al., 2001). In contrast, post-mortem
ﬁndings from brains of cocaine addicted individuals revealed
upregulated D3 receptors (Staley and Mash, 1996). PET imaging
studies in cocaine (Payer et al., 2014) and in methamphetamine
polydrug users (Boileau et al., 2012; Matuskey et al., 2013) have
conﬁrmed this up-regulation. It is likely that this regulation is due
to drug exposure, as various drugs of abuse, such as cocaine (Le
Foll et al., 2002), methamphetamine (Le Foll et al., 2005b), nico-
tine (Le Foll et al., 2003), and alcohol (Leggio et al., 2014) produce
this up-regulation.
With respect to schizophrenia, both D2 and D3 receptors are
upregulated in post-mortem brains but the level of D3 receptors
appear equivalent to controls in patients that had received antipsy-
chotic treatment prior to death (Joyce et al., 1988). This highlights
differences in the response to treatment betweenD2 andD3 recep-
tors. Consistent with this, there were also no differences between
controls and schizophrenics who received treatment in the binding
of [125]trans-7-OH-PIPAT to D3 DA receptors (Gurevich et al.,
1997).
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In Parkinson’s disease, there is a clear up-regulation of the D2
receptor and down-regulation of the D3 receptor (Levesque et al.,
1995; Morissette et al., 1998; Boileau et al., 2009). Administration
of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to non-
human primates produces a syndrome that resembles Parkinson’s
disease (postural rigidity, bradykinesia, and akinesia) in humans
and is thus used as a model of this disease. When given MPTP
unilaterally, symptoms canbeobservedonone sideof thebody and
neurochemical correlates can be compared to the non-lesioned
side. In monkeys given unilateral MPTP, an up-regulation of D2
receptors was found in the lateral caudate and putamen (Joyce
et al., 1986; Graham et al., 1990) of the treated hemisphere. This
up-regulation was also found when DA levels were reduced due
to 6-OHDA-induced denervation (LaHoste and Marshall, 1991).
In contrast to the ﬁndings with D2 receptors, D3 receptors were
down-regulated in the ipsilateral nucleus accumbens following a
6-OHDA lesion while D2 receptors were upregulated (Levesque
et al., 1995). Similarly, the brains of Parkinson’s disease patients
show increased D2 receptor density and decreased D3 receptors
(Ryoo et al., 1998).
Effects on drug taking behaviors
There is considerable pre-clinical evidence suggesting that D3
receptor antagonists may be effective as treatments for addiction.
Several reviews have proposed that D3 receptor antagonists may
reduce relapse to the seeking of a variety of classes of drugs (Heid-
breder et al., 2005; Le Foll et al., 2005c, 2007; Newman et al., 2005).
D3 receptor antagonists may be especially effective in alleviating
craving and relapse induced by conditioned stimuli (Le Foll et al.,
2005c) in the environment and thus may block the drug-seeking
induced by images and/or events associatedwith the drug of abuse.
The intravenous self-administration paradigm is a widely used
model of drug addiction in which animals are trained to learn a
new response that supplies or yields a bolus of drug. Although
this model has face validity (i.e., it looks like what it supposed
to measure), the effects of treatments on self-administration are
not always intuitive in a simple way. Although treatments that
block the reinforcing effects of drugs of abuse may decrease
the amount of drug self-administered, they may also increase
drug self-administration as the animal “compensates” for the
reduced potency of the drug (Pickens and Thompson, 1968;
Corrigall and Coen, 1989). Thus, treatment strategies that block
the rewarding effects of a drug may actually lead to its increased
self-administration.
These compensatory increases in behavior have been a disad-
vantage of D2 receptor antagonists, as opposed to D3 antagonists,
in pre-clinical models. That is, blockade of the D2 DA receptor
resulted in increases in responding for amphetamine (Yokel and
Wise, 1975), MDMA (Brennan et al., 2009), methamphetamine
(Brennan et al., 2009), or cocaine (Woolverton, 1986). By contrast,
blockade of D3 receptors with selective D3 receptor antagonists
hadno effect on the self-administrationof nicotine (Andreoli et al.,
2003), cocaine (Di Ciano et al., 2003; Gal and Gyertyan, 2003; Xi
et al., 2005; Achat-Mendes et al., 2010), methamphetamine (Orio
et al., 2010; Higley et al., 2011), or amphetamine (Higley et al.,
2012). It should be noted that one study found a decrease in the
self-administration of cocaine when the animal was required to
make more responses for drug (Xi et al., 2005), suggesting that
instances requiring high effort to obtain drug may be affected by
D3 antagonists. Further, it has been reported that D3 blockade by
the selective D3 antagonist SB-277011-A decreased alcohol self-
administration under low schedules of reinforcement (Thanos
et al., 2005; Heidbreder et al., 2007). More recently, studies with
D3 deﬁcient mice have revealed that the D3 receptor is neces-
sary for alcohol consumption (Leggio et al., 2014). The reason for
the discrepancy between the alcohol ﬁndings and those of other
drugs is unknown, but together these ﬁndings suggest that, unlike
D2 receptor antagonists, D3 antagonists do not increase intake of
drugs of abuse andmay serve as good pharmacological treatments.
In sum, the distinction between D2 and D3 receptor antagonists
may be important when devising treatments for addiction.
Effects on locomotor activity and catalepsy
Dopamine antagonists can produce undesirable effects on loco-
motor activity; however, these effects are absent with D3 antago-
nists. Decreases in locomotor activity can be viewed as a measure
of the non-speciﬁc, i.e., D2, effects of treatments and can be an
indication that these antagonists will have undesired side effects.
D2 antagonists have a well-known ability to reduce locomotion
and induce catalepsy. By comparison, administration of D3 antag-
onists have no effects on spontaneous locomotion (Reavill et al.,
2000; Le Foll et al., 2005a; Xi et al., 2005), stimulant-induced loco-
motion (Reavill et al., 2000), and are non-cataleptogenic (Vorel
et al., 2002; Xi et al., 2005). Indeed, comparison of the D3 antag-
onist SB-277011-A to the D2 antagonist haloperidol revealed no
ability to produce catalepsy of the former and signiﬁcant catalep-
tic effects of the latter (Reavill et al., 2000). The D2 antagonist
L741626 has also been observed to produce catalepsy, however, the
D3 antagonists PG01037 and S33084 did so as well but to a lesser
extent (Millan et al., 2000; Achat-Mendes et al., 2010). D2 antago-
nists blocked stimulant-induced locomotion while D3 antagonists
had no effect (Millan et al., 2000). However, one study found
decreases in nicotine-induced locomotion with the D3 antago-
nist SB-277011-A (Ross et al., 2007) used at high doses which may
not be selective while another study found that the D3 antag-
onist NGB 2904 potentiated amphetamine-induced locomotion
(Pritchard et al., 2007).
Selectivity of effects
Another approach to demonstrate that D3 antagonists lack non-
speciﬁc effects is through evidence revealing that their effects are
selective to the behavior under study. In the case of drug addic-
tion, D3 antagonists hold promise because they seem to affect
drug-relevant behaviors while sparing behaviors motivated by
natural reward. This provides support not only for selectivity
of effects but also makes the point that D3 antagonists, used
as a treatment for drug addiction, will not have general effects
on motivation. One of the most consistently reported effects of
D3 antagonists is their ability to block drug-seeking behaviors
in animal models of relapse (i.e., reinstatement of drug-seeking
behaviors; Vorel et al., 2002; Andreoli et al., 2003; Xi et al., 2004,
2006; Gilbert et al., 2005; Gal and Gyertyan, 2006; Heidbreder
et al., 2007; Achat-Mendes et al., 2010; Khaled et al., 2010; Higley
et al., 2011, 2012). Importantly, this effect of reduced seeking to
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various drugs of abuse appears speciﬁc as no effect on food seeking
behavior has been reported (Gal andGyertyan,2006; Xi et al., 2006;
Cervo et al., 2007). Similarly, D3 antagonists are effective in block-
ing drug-seeking behaviors maintained by conditioned stimuli
under second-order schedule of reinforcement, while producing
no effects on responding for sucrose under a similar schedule of
reinforcement (Di Ciano et al., 2003).
In contrast, D2 antagonists appear non-selective in their effects.
That is, spiperone, haloperidol, L741626, or pimozide decreased
food intake (Wise et al., 1978; Corrigall and Coen, 1991; Achat-
Mendes et al., 2010). Interestingly, the latter study did not observe
any effects on the ﬁrst day of testing, with effects being observed
only after repeated exposure of the animals to responding for
food under the effects of pimozide, which suggests that D2/3
receptors are involved in the learning of this behavior. This may
explain the lack of effect of eticlopride on food intake following
a single treatment (Ball et al., 2011). However, eticlopride also
decreased responding on a ﬁrst test session when the animals were
required to make a more complex response for food (Caine and
Koob, 1994). Administration of haloperidol did not effect rein-
statement induced by a sucrose-paired conditioned stimulus (Gal
and Gyertyan, 2006), while eticlopride either increased (Ball et al.,
2011) reinstatement induced by a food-paired CS or decreased it
(Liu et al., 2010). Thus, D2 antagonists may be less selective and
affect non-speciﬁc aspects of motivation that are absent with the
highly selective D3 antagonists.
Effects on cognition
Evidence suggests that D3 antagonists may improve cognitive per-
formance and thus may be viable treatments for pathologies with
considerable cognitive deﬁcits (dementia or schizophrenia; see
Nakajima et al., 2013 for a review). For example, memory can be
tested by imposing a delay between training and testing conditions.
In the social recognition test, animals are presented with a novel
juvenile rat and allowed to explore the juvenile. At a later point,
the juvenile is re-introduced and exploration time of the juvenile
is measured; if the animal spends less time exploring the animal
than it did during the ﬁrst exposure, then memory of the juve-
nile is intact. By increasing the delay between presentations of the
juvenile, the memory for the juvenile is lost and exploratory time
increases. Administration of D3 antagonists S33084 or SB-277011-
A enhanced the memory for the juvenile after a delay (Millan et al.,
2007).
Relative to D2 antagonists, D3 antagonists also ameliorated
cognitive performance in the novel object discrimination task.
In this model, time spent in exploration of a novel object is
compared to exploratory time with a familiar object. Given that
animals explore novel objects, they should spend more time
exploring a novel object if the animal remembers the object with
which it has previous exposure. Using this task, it was revealed
that impairments in this task caused by a delay in the expo-
sure and test trials were reversed by a D3 antagonist S33084.
By contrast, normal performance observed without a delay was
impaired by the D2 antagonist L741626 (Watson et al., 2012a).
Similarly, when impairments in novel object recognition were
imposedby isolation rearing,D3antagonists also enhancedperfor-
mance while D2 antagonists impaired performance under control
conditions (Watson et al., 2012b). Based on these and other obser-
vations (Nakajima et al., 2013), we and others have proposed that
D3 antagonists, but not D2 antagonists, may serve as cognitive
enhancers.
RECEPTOR OCCUPANCY IN ANIMALS
Pre-clinical studies have established the importanceof functionally
distinguishing D3 from D2 receptors. In basic pharmacological
experiments, the ability of a compound to bind to D3, as opposed
to D2, receptors, can be measured by studying its afﬁnity for these
different receptors. However, demonstrating that a compoundwill
bind to D3 receptors at a given dose is essential to establish that the
receptor is really occupied by the drug. Measurement of D3 recep-
tor occupancy has been difﬁcult due to the lack of radioligands
selective for D3 over D2 receptors. The recent advent of [11C]-
(+)-4-propyl-9-hydroxynaphthoxazine ([11C]-(+)-PHNO; Wil-
son et al., 2005), a D3 preferring agonist (Narendran et al., 2006),
allows for the measurement of occupancy of D3 receptors. Speciﬁ-
cally, the occupancy of D3 antagonists in various brain areas can be
evaluated by measuring [11C]-(+)-PHNO binding in the presence
or absence of drug. In a study by Kiss et al. (2011), [3H]-(+)-
PHNO binding in various brain areas was antagonized by either
the D3 antagonist SB-277011-A or the D2 antagonist SV-156 to
determine whether binding of [3H]-(+)-PHNO was due to occu-
pation of D2 or D3 receptors. They found that [3H]-(+)-PHNO
binding in the rat cerebellar lobules 9 and 10 but not in the stria-
tum was blocked by administration of a D3 antagonist, whereas
the opposite was true for a D2 antagonist (Kiss et al., 2011). These
results suggest that [3H]-(+)-PHNObinding in the cerebellar lob-
ules 9 and 10 is due to D3 receptors while [3H]-(+)-PHNO binds
to D2 receptors in the striatum. Thus, it is possible to estimate the
amount of binding of a D3 antagonist by measuring occupancy of
D3 receptors by [3H]-(+)-PHNO in cerebellar lobules 9 and 10,
and conversely, to estimate occupation of D2 receptors by binding
of [3H]-(+)-PHNO in the dorsal striatum.
This is consistent with the demonstration that SB-277011-A
decreased binding of [3H]-(+)-PHNO in various brain areas with
the greatest reduction being observed in the D3-rich substantia
nigra and ventral tegmental area, and the least reduction being
observed in the ventral striatum and D2-rich caudate/putamen
(Rabiner et al., 2009). The binding pattern of [3H]-(+)-PHNO
following the D2 antagonist SV-156 was complementary to that
following SB-277011-A, with the most reduction in binding being
observed in the dorsal striatum (Rabiner et al., 2009). Similarly,
in knockout mice lacking the D3 receptor, binding of [3H]-(+)-
PHNO was reduced in the ventral striatum and extra-striatal
regions, while it was reduced in the ventral striatum and dorsal
caudate-putamen in mice lacking the D2 receptor (Rabiner et al.,
2009). Thus, reciprocal differences are observed in the binding of
[3H]-(+)-PHNO in the brain. Occupancy of D3 receptors in rats
can be measured by analysis of the cerebellar lobules 9 and 10 and
binding of D2 receptors to the dorsal striatum.
Application of these principles has been used to measure the
occupancy of D3 receptors by the D3 antagonist, SB-277011-A
in a study by McCormick et al. (2013). To achieve this, rats were
pre-treated with 10 mg/kg SB-277011-A. Sixty minutes following
pre-treatment, rats were injected with [3H]-(+)-PHNO in the
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tail vein (intravenous injection) and a further 60 min allowed
for uptake of the tracer. Rats were then killed by decapitation
and brain areas of interest excised. Neural regions in which [3H]-
(+)-PHNO binds to D2 receptors, namely, the dorsal striatum
and nucleus accumbens, were excised. The cerebellar lobules 9
and 10, where binding is to D3 receptors, were also excised. By
comparison of the binding to D3 receptors by [3H]-(+)-PHNO
in the various brain areas it was possible to estimate the amount
of occupancy of D3 receptors. As can be seen in Figure 2, it was
reported that binding of [3H]-(+)-PHNO in cerebellar lobules
9 and 10 was low after administration of 10 mg/kg SB-277011-
A, suggesting that this D3 antagonist occupies D3 receptors and
competes with [3H]-(+)-PHNO which is displaced. Binding of
[3H]-(+)-PHNO in the striatum andnucleus accumbenswas high
after 10 mg/kg SB-277011-A, suggesting that this compound does
not readily compete with [3H]-(+)-PHNO for D2 receptors in
these areas at this dose (McCormick et al., 2013). Collectively, these
ﬁndings conﬁrm that SB-277011-A is a D3 antagonist with high
afﬁnity for D3 receptors over D2 receptors (Reavill et al., 2000).
This approach has also been used to explore the binding of
another D3 antagonist, GSK598809, in rats. In this study, binding
of the radiotracer [11C]-(+)-PHNO toD3 receptorswas decreased
in humans after treatment with the D3 antagonist GSK598809
(Mugnaini et al., 2013). Notably, this study took a translational
approach and demonstrated that administration of GSK598809
to rats disrupted a conditioned place preference for a nicotine-
paired environment and that this ability was observed with doses
which result in selective D3 occupancy (Mugnaini et al., 2013).
Conditioned place preference is a model of addiction and the abil-
ity of environmental stimuli to induce approach behaviors after
association with drug (Le Foll and Goldberg, 2005). This ﬁnd-
ing is consistent with the hypothesis that D3 antagonists may be
especially involved in the conditioned learning of associations in
addiction (Le Foll et al., 2005c).
PET IMAGING IN HUMANS
Another method to measure occupancy of D3 receptors is through
in vivo methods such as PET imaging in humans. PET permits
FIGURE 2 | In vivo method for occupancy of D3 in rats. [3H]-(+)-PHNO
speciﬁc binding ratio in dorsal striatum, nucleus accumbens, and cerebellar
lobules 9 and10 (Lob 9 & 10) after pretreatment with vehicle (veh) or the
selective D3 antagonist SB-277011-A (SB). Graphs depict mean ± SD.
**p < 0.01 compared to the vehicle-treated group. Adapted from
McCormick et al. (2013).
the measurement of neurochemicals in vivo and has become a
powerful tool for neuroscientists to visualize and localize recep-
tors, measure enzymatic activity, and estimate endogenous levels
of neurotransmitters (Frankle and Laruelle, 2002; Parsey and
Mann, 2003; Volkow et al., 2003a,b). In PET imaging, a positron-
emitting radiotracer (e.g., [11C]-raclopride or [11C]-(+)-PHNO)
that binds to the protein of interest (e.g., D2 or D3 receptors),
is injected intravenously and the binding of this radiotracer to
receptors can bemeasured using the PET scanner. TheD2/3 recep-
tors were the ﬁrst to be imaged using [11C]-N-methylspiperone
in the living human brain using PET (Wagner et al., 1983). Since
then a number of new radioligands to measure these receptors
have been developed, e.g., [18F]-FESP, [11C]-raclopride, [11C]-N-
methylbenperidol, [11C]-FLB 457, [18F]-fallypride (Ehrin et al.,
1985; Coenen et al., 1987; Suehiro et al., 1990; Halldin et al., 1995;
Mukherjee et al., 1997). Since PET imaging measures the binding
of a radioligand to a receptor, changes in binding over time can
be attributed to up-regulation or down-regulation of the receptor.
However, PET imaging is a competitive measure, in that endoge-
nous DA competes with the radioligand for the receptor, thereby
providing an indirect measure of DA levels. The amount of bind-
ing of the radioligand is inversely proportional to the amount of
neurotransmitter present such that decreases in binding of the
radioligand to receptors infer an increase in DA levels.
There are two caveats to this approach: (1) although changes
in DA levels can be inferred, the mechanism by which the neu-
rotransmitter is changed is unknown. In hypothesizing whether
changes are due, for example, to altered release or re-uptake, ref-
erence to pre-clinical ﬁndings must be made; and (2) since PET
imaging, strictly speaking, measures binding of a radioligand to a
receptor, changes in binding can be due to receptor adaptations.
Thus, PET studies have within them an inherent problem of inter-
pretation: are changes in binding potential due to altered synaptic
DA or due to changes in the levels of the receptor? In general,
changes in binding potential following administration of an acute
challenge, for example, methylphenidate (Martinez et al., 2011),
can be assumed to be related to altered DA transmission because
the time frame of treatment is not long enough to observe altered
regulationof the receptor. However,more long-termchanges, such
as those produced by chronic treatments (Brody et al., 2010), are
more difﬁcult to interpret, and parallels with the animal litera-
ture or post-mortem ﬁndings in humans can be informative. For
a more detailed description of these caveats in PET imaging, see
(Morris et al., 2013). Each of these approaches (measurement of
DA levels and of D3 receptor levels) is considered further below.
Increased sensitivity in the detection of DA levels with
[ 11C]-(+)-PHNO
The DA system, and in particular, D2/3 receptors, is one of the
most extensively imaged receptor systems in the brain. The tra-
ditional radioligand that has been used is [11C]-raclopride. One
limitation of PET imaging is that the sensitivity to detect changes
in DA levels is low compared to that observed in animal studies,
and a ceiling effect of around 40% change in receptor binding is
observed (reviewed in Martinez and Narendran, 2010). Recently,
[11C]-(+)-PHNO, a selective D3 agonist for use in PET stud-
ies with humans, has been characterized (Narendran et al., 2006;
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Willeit et al., 2006; Ginovart et al., 2007). Recent evidence sug-
gests that this agonist radioligand [11C]-(+)-PHNO enables the
detection of smaller changes in synaptic DA levels with greater
sensitivity as compared to [11C]-raclopride. This is supported by
the direct comparison of the dose-effect of amphetamine (0.1, 0.5,
and 2 mg/kg; i.v.) on binding of [11C]-(+)-PHNO and [11C]-
raclopride in cats (Ginovart et al., 2006). We also have recently
shown enhanced ability of [11C]-(+)-PHNO to detect elevation
of DA induced by smoking (Le Foll et al., 2014). Thus, the advent
of [11C]-(+)-PHNO has allowed for a more sensitive measure of
changes in DA levels than previously available radioligands.
Measurement of D3 receptors with [ 11C]-(+)-PHNO
Positron emission tomography imaging of D3 receptors in humans
has previously been problematic due to the lack of radiotrac-
ers selective for D3 over D2 receptors. In addition to increased
sensitivity in measuring DA levels, PHNO is also more selec-
tive for D3 receptors, allowing quantiﬁcation of receptor levels.
Importantly however, the brain areas under investigation must
be carefully considered, as the selectivity varies depending on the
region of interest. D3, as compared to D2, signal is highest in
the substantia nigra, hypothalamus and ventral pallidum, moder-
ate in the globus pallidus and low/absent in the human striatum
(Tziortzi et al., 2011). Consistent with the binding studies in ani-
mals, in vivo PET studies in humans found that [11C]-(+)-PHNO
binding in the dorsal striatum was due to D2 receptors (Gino-
vart et al., 2007), while binding in the globus pallidus was due
to D3 receptors [Narendran et al., 2006; see the elegant study
of Tziortzi et al. (2011) for a dissection of D3 contribution to
[11C]-(+)-PHNO signal]. [11C]-Raclopride, a radiotracer with
equal afﬁnity for the D2 and D3 receptors, bound more in the
striatum (Graff-Guerrero et al., 2008), conﬁrming the selectiv-
ity of binding in this region for the D2 receptor. This is further
supported by the ﬁnding that [11C]-(+)-PHNO binding in the
substantia nigra is blocked by the D3 receptor antagonist SB-
277011-A in non-human primates (Rabiner et al., 2009). Thus,
in estimating occupancy of D3 receptors, binding of [11C]-(+)-
PHNO in the substantia nigra or globus pallidus can be measured,
whereas [11C]-(+)-PHNO can also be informative as to occu-
pancy of D2 receptors by measuring binding in the striatum.
However, it should be noted that binding of [11C]-(+)-PHNO is
not complete in all areas. Although the displacement of [11C]-
(+)-PHNO by SB-277011-A is almost 100% in the substantia
nigra and ventral tegmental area, only around 80% of the sig-
nal in the globus pallidus is attributable to the D3 receptor in
mouse and baboon (Rabiner et al., 2009). This contribution is
much less in the ventral striatum (around 50–60%) and even less
in caudate-putamen (20–40%), consistent with the lack of selec-
tivity of [11C]-(+)-PHNO forD3 receptors in these areas (Rabiner
et al., 2009). Figure 3 provides an illustration of the regional bind-
ing of [11C]-(+)-PHNO in the human brain. As can be seen,
binding is highest in substantia nigra, globus pallidus, and ven-
tral striatum; as such, changes in binding in these areas can reveal
the degree to which a treatment is selective for D3 receptors. By
comparison to areas in which [11C]-(+)-PHNO binding is to D2
receptors, imaging with [11C]-(+)-PHNO can provide a measure
of the occupancy of D2 vs. D3 receptors, which is not provided by
[11C]-raclopride.
In a study by Searle et al. (2010), the competition of a selective
D3 antagonist, GSK598809, with [11C]-(+)-PHNO was quanti-
ﬁed in various brain regions and correlated with plasma levels
of GSK598809. In this study, binding of [11C]-(+)-PHNO to
receptors was expressed as displacement – the degree to which
[11C]-(+)-PHNO binding was prevented by the antagonist. Thus,
the greater the displacement of [11C]-(+)-PHNO, the greater the
binding of GSK598809 to receptors. As can be seen in Figure 4
(left panels), a correlation of plasma levels of GSK598809 and dis-
placement of [11C]-(+)-PHNO binding to the D2/3 receptor is
given. Binding of GSK598809 was greatest in the substantia nigra
and also apparent in the globus pallidus, as compared to mini-
mal binding in the ventral striatum, thalamus, dorsal caudate, and
dorsal putamen. These results indicate that GSK598809 is acting
primarily on the substantia nigra, then the globus pallidus and
very little in the caudate, consistent with the ability to measure
binding to D3 receptors [11C]-(+)-PHNO in the substantia nigra
(Searle et al., 2010).
FIGURE 3 |Vizualing D3 in humans with [11C]-(+)-PHNO. Uptake value mean images from 12 healthy controls. Note the preferential distribution in the
substantia nigra, globus pallidus, and ventral striatum. Adapted with permission from Graff-Guerrero et al. (2008).
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FIGURE 4 | Plots of [11C]-(+)-PHNO displacement against plasma
concentration of GSK598809 or ABT-925 in two brain regions.
Relationship of [11C]-(+)-PHNO displacement to plasma levels of
GSK598809 (left panels) and ABT-925 (right panels) in the substantia
nigra (top panels) or caudate (bottom panels). At high concentrations,
GSK598809 and ABT-925 almost completely blocked the speciﬁc
binding of [11C]-(+)-PHNO in substantia nigra, with negligible effects
on the caudate for GSK598809 and limited effect on the caudate for
ABT-925. With permission from Searle et al. (2010) and Graff-Guerrero
et al. (2010).
The ability to conduct occupancy studies with D3 antagonists
in humans was also demonstrated with the administration of a
selective D3 antagonist, ABT-925 (Graff-Guerrero et al., 2010).
Receptor occupancy by ABT-925 was higher in the globus pal-
lidus and substantia nigra than in caudate, putamen or ventral
striatum, indicating binding of ABT-925 to D3 receptors. By com-
parison, ABT-925 was bound minimally in areas where binding
is to D2 receptors, the ventral striatum, putamen, and caudate.
ABT-925 dose-dependently bound to areas where binding is due
to D3 receptors, the globus pallidus and substantia nigra, revealing
the selectivity of [11C]-(+)-PHNO for the D3 receptor (Figure 4,
right panels). It should be noted that these ﬁndings have been
called in to question by Rabiner and Laruelle (2010), a position
that has been countered (Day et al., 2010).
A recent study has been conducted with the selective D3 antag-
onist GSK598809 to demonstrate its binding to D3 receptors and
correlate this with clinical efﬁcacy. In this study, marked changes
in binding were observed in the substantia nigra, moderate bind-
ing was observed in the globus pallidus and marginal changes
were found in the dorsal striatal regions (Searle et al., 2010). Thus,
binding of GSK598809 was to D3 receptors preferentially. In a
subsequent study, binding of GSK598809 to D3 receptors was
conﬁrmed and extended to include behavioral tests in humans
(Mugnaini et al., 2013). In that study, it was found that while
under the inﬂuence of GSK598809, smokers actually increased
their rate of smoking. Although this may seem contrary to the
expected effects of a drug that blocks the effects of drugs, the
authors propose that increases in smoking may be compensatory
due to a reduced efﬁcacy of cigarettes to deliver their reinforcing
effects. As discussed above, this is not a desirable effect and one
that is associated with D2 receptor antagonism in animals, not
D3 receptor antagonism. However, cigarette smoking was assessed
at about 8–19 h post-dose with GSK598809, and the possibil-
ity exists that a different time course of the drug administration
may yield different effects. Further, clinical trials of drug efﬁ-
cacy for reducing smoking generally tend to assess smoking in
the natural environment at several weeks during and after drug
administration. Thus, further and more extensive clinical trials on
the effects of D3 antagonists on drug intake are warranted, espe-
cially given the promising ﬁndings in pre-clinical studies (reviewed
above).
The reasons for the termination of clinical trials with D3 agents
are unknown, but it is promising that some trials showed efﬁcacy,
with one reporting a reduction in cigarette craving (Mugnaini
et al., 2013), and the other reporting reductions in attentional
bias to food cues in some populations (Nathan et al., 2012).
These ﬁndings are tempered somewhat by further reports that,
despite attenuated craving following GSK598809, cigarette smok-
ing increased (see discussion above; Mugnaini et al., 2013) while
GSK598809 did not alter brain responses to food images in obese
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patients (Dodds et al., 2012). These mixed ﬁndings, despite being
preceded by great theoretical interest, warrant further study of D3
agents.
ROLE OF D3 RECEPTORS: STUDIES WITH [11C]-(+)-PHNO
We have begun to use these imaging tools to determine the role of
the D3 receptor, as compared to the D2 receptor, in addictive dis-
orders. In our studies, we measured binding to D3 receptors using
[11C]-(+)-PHNO and to D2 receptors using [11C]-raclopride,
or compared [11C]-(+)-PHNO binding in D3-rich (substantia
nigra) vs. D2-rich (striatum) areas, to determine the relative role of
these receptors in addictive behaviors. To do this, we have studied
not only cocaine and methamphetamine abusers, but also patho-
logical gamblers, as gambling being recently classed as an addictive
disorder in the DSM-5 (American Psychiatric Association, 2013).
In our initial study, we examined [11C]-(+)-PHNO binding
in methamphetamine polydrug users and found that metham-
phetamine use was correlated with signiﬁcantly higher [11C]-(+)-
PHNO binding in the D3-rich substantia nigra as compared to
healthy controls (Boileau et al., 2012). Since increased [11C]-(+)-
PHNO binding can reﬂect either lower DA levels or increased
number of receptors, these ﬁndings can be interpreted either way
at ﬁrst glance. However, pre-clinical (Le Foll et al., 2002) and
post-mortem (Staley and Mash, 1996) studies have been con-
sistent in ﬁnding increased D3 receptor number in the brains
of drug-exposed individuals, suggesting that our ﬁndings with
[11C]-(+)-PHNO reﬂect an up-regulation in D3 receptor num-
ber. Also consistent with established ﬁndings (Volkow et al., 2001),
[11C]-(+)-PHNO binding in the D2-rich area of the striatum was
decreased in heavy methamphetamine users. Together, the results
of our study not only conﬁrm those of past studies, but pro-
vide the ﬁrst in vivo evidence in humans of an up-regulation of
D3 receptors in addicted individuals, an effect that was oppo-
site to that found for D2 receptors. Indeed, in a follow-up study
with cocaine dependent individuals (Payer et al., 2014), partici-
pants also had increased [11C]-(+)-PHNO binding in the D3-rich
substantia nigra as compared to controls, while [11C]-raclopride
binding was decreased in the D2-rich striatum, as consistent with
previous reports (Volkow et al., 2001). Together, these studies
suggest that treatments targeting the DA system in general may
not be the best strategy. That is, these approaches may produce
the same response in both D2 and D3 receptors (i.e., compen-
satory increases in both receptor subtypes). Rather, the present
ﬁndings suggest that strategies differentially affecting D2 vs. D3
receptors would be preferable. More selective approaches are
needed.
Most interesting for the present discussion are ﬁndings that
D3 binding in cocaine-dependent participants correlate with the
number of risky choices on the Game of Dice task (a measure of
risky decision making) and with errors on the Continuous Per-
formance Task (a measure of attention and inhibitory control;
Payer et al., 2014). Together, these ﬁndings implicate a relationship
between D3 receptor levels and risky decision making, suggesting
perhaps an addictive phenotype in that D3 receptor levels may
be related to impulsivity/risky decision making. This is echoed in
the additional ﬁnding that binding in D3-rich areas was correlated
with motivation to use methamphetamine (Boileau et al., 2012),
and, to a lesser extent, amphetamine-induced “rush,” indicating a
functional relevance of up-regulation of D3 receptors.
Indeed, in pathological gamblers, we found that [11C]-(+)-
PHNO binding in the D3-rich substantia nigra was correlated
with self-reported impulsivity and severity of gambling (Boileau
et al., 2013a). It should be noted that, in this study, there were no
overall differences in [11C]-(+)-PHNO binding between patho-
logical gamblers and healthy controls, suggesting a difference
between methamphetamine and cocaine addictions and an addic-
tion to gambling. These differences may reﬂect pharmacological
factors related to the presence of drug in the body and receptor
regulation in response to this. Further evidence for a difference
between drug abusers and gamblers was found in a recent study.
We demonstrated that in response to an amphetamine challenge,
[11C]-(+)-PHNO binding in the striatum was decreased to a
greater degree in the brains of gamblers compared to healthy con-
trols, presumably due to increasedDA levels (Boileau et al., 2013b).
This is opposite to evidence that dopaminergic responses to chal-
lenges are blunted in the brains of drug addicts (Volkow et al.,
2001; Martinez et al., 2005, 2007). As mentioned above, changes
in [11C]-(+)-PHNO binding can reﬂect either receptor density
or DA levels, as alterations in either will affect [11C]-(+)-PHNO
binding. In these cited studies, since the measurements are in
response to an acute challenge and under this time course it can be
assumed rapid changes in [11C]-(+)-PHNO binding are unlikely
to reﬂect receptor internalization. Thus these changes can be said
to be due to greater increases in DA levels in pathological gamblers
vs. healthy controls. In sum, gamblers have no differences in D3
receptor number as compared to controls, whereas drug addicts
have upregulated D3 receptors. Further, DA efﬂux in response to
a drug challenge is blunted in drug addicts, while it is augmented
in gamblers. Nonetheless, the relationship of [11C]-(+)-PHNO to
impulsiveness may be a common factor, suggesting that the cor-
relation of D3 receptor binding to impulsiveness may highlight a
phenotype susceptible to addictions. [11C]-(+)-PHNO has also
been used to demonstrate that smoking elevates DA at the level of
the D3 receptor in the human brain (Le Foll et al., 2014), an effect
that conﬁrms its relevance for nicotine addiction treatment.
CONCLUSION
Since the cloning of theD3 receptor by Sokoloff et al. (1990),much
more information is now available on its role. Pre-clinical stud-
ies have clearly delineated a role for D3 receptors in drug-seeking
behavior and in motivation to take drugs. There is a clear disso-
ciation in the functional role of D2 vs. D3 (Le Foll et al., 2009)
not only for addiction, but also for other important functions
such as cognition and motor control, and these ﬁndings have
possible implications for treatment of schizophrenia, dementia,
and Parkinson’s disease. It is therefore of foremost importance
that these pre-clinical ﬁndings be translated into clinical studies.
However, one caveat of previous studies has been that putative
D3 ligands were used at doses that did not selectively occupy the
D3 receptor (Graff-Guerrero et al., 2010). Here, we propose that
the use of recently developed methods using [3H]-(+)-PHNO in
both pre-clinical studies and human imaging studies should be
incorporated. This is important in testing of highly selective D3
ligands to ensure appropriate doses are chosen. It is also useful
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for ligands such as buspirone, that have shown to have some D3-
related effects, to determine the contribution between D2 and D3
receptors (Bergman et al., 2013; Le Foll and Boileau, 2013; Leggio
et al., 2014).
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